VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc., herein referred to as “BioNxt” or “the Company” (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), an innovator in bioscience specializing in advanced drug delivery systems, is pleased to announce it has received a “Readiness to Grant” notification from the Eurasian Patent Organization (EAPO). This notification pertains to the Company’s comprehensive patent application for the sublingual administration of anticancer medications used in treating autoimmune neurodegenerative conditions. This patent family presents several exclusive avenues for product development and commercialization, notably including BioNxt’s primary product, BNT23001, which is a sublingual thin-film version of Cladribine intended for multiple sclerosis (MS) treatment.
BioNxt anticipates the EAPO will officially issue the patent once a publication fee is paid, which the Company plans to remit to the EAPO within the current week. The EAPO’s jurisdiction extends across Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan. These nations are signatories to the Eurasian Patent Convention (EAPC), which establishes a unified, standardized patent application system and regulatory body for the area. Eurasian patents granted by the EAPO are effective in all eight member countries, collectively home to over 200 million people.
“Securing patent protection is vital to our commercialization approach,” stated Hugh Rogers, CEO of BioNxt. He added, “This timing is highly opportune, as the Company is just days from starting a two-week large-animal bioequivalence study designed to establish dosing guidelines for our forthcoming human bioequivalence study. BioNxt anticipates a period of significant progress in the coming months as numerous clinical programs move forward and our intellectual property holdings achieve global recognition and safeguarding.”
The procedure for nationalizing the patent is currently in progress across significant global markets, such as the European Union, Canada, Australia, Eurasia, New Zealand, and Japan. Additionally, a Track One priority application has been submitted in the United States. Both the European Patent Office and the Eurasian Patent Office have provided positive feedback, formally acknowledging the novelty, inventive aspect, and industrial applicability of the patent.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. stands as a bioscience innovator dedicated to pioneering advanced drug delivery methods, diagnostic screening technologies, and the creation of active pharmaceutical ingredients. The Company’s distinct platforms—Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)—are engineered to address critical therapeutic areas such as autoimmune diseases, neurological conditions, and factors related to longevity.
Operating research and development facilities in both North America and Europe, BioNxt is actively pursuing regulatory approvals and commercialization initiatives, with a primary emphasis on European markets. BioNxt is dedicated to elevating healthcare standards through the provision of accurate, patient-focused solutions designed to better treatment results globally.
BioNxt’s shares are listed on the Canadian Securities Exchange under BNXT, on OTC Markets as BNXTF, and are traded in Germany with WKN: A3D1K3. For further information about BioNxt, please visit .
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email:
Phone: +1 778.598.2698
Web:
LinkedIn:
Instagram:
Cautionary Statement Regarding “Forward-Looking” Information
This press release includes forward-looking statements as defined by relevant securities legislation. These statements encompass information concerning the development, trials, regulatory clearance, and commercialization of BioNxt’s sublingual drug offerings, alongside anticipated milestones, prospective collaborations, and potential market prospects. Forward-looking statements inherently involve considerable risks, uncertainties, and presumptions, many of which lie outside BioNxt’s influence. Elements that could lead to actual results varying substantially include, but are not limited to, holdups in regulatory approvals, unfavorable outcomes from clinical investigations, shifts in market demand, variations in funding accessibility, or interruptions in supply chains. Readers are advised against placing excessive trust in these forward-looking statements, as actual results could diverge significantly from those stated or implied. BioNxt is under no obligation to amend or update forward-looking statements, except where mandated by law. Other factors that could lead to actual results differing substantially from projections include alterations in market demand, regulatory changes, postponements in clinical trials, swings in financing availability, disruptions to the supply chain, and unforeseen competitive challenges.
SOURCE: BioNxt Solutions Inc.